Orion Corp New B Shs (ORINF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and greetings from sunny Helsinki. Welcome to Orion's half-year financial report January June 2026 conference call and webcast. My name is Tuukka Hirvonen and I'm the head of IR here at Orion. In a few moments, our CEO Liisa Hurme will go through the results and key events of the reported period after which you will have then the possibility to ask questions in the Q&A session from Liisa and also from CFO Rene Lindell. There's a possibility to ask questions through the conference call lines but also by typing them in through the chat function in the webcast. We will start with the conference call lines and then turn on to the webcast chat. For our Finnish viewers information that there will be a Finnish speaking interview of CEO Liisa Hurme available on Orion's internet page later this afternoon. and just before letting Liisa to take over a brief reminder about the forward-looking statements in the presentation and with these words it's my pleasure to hand over to Liisa. Thank you Tuukka and good afternoon on my behalf as well. We have once again delivered a strong quarter. Our net sales growth accelerated and also profitability improved during Q2. This was driven by Nubeca royalties and product sales, and also our brandy products division had an excellent quarter. In research and development, we reached several key milestones, especially with ODM212, and I will discuss that molecule later on in more detail. In Q2, Our net sales increased by 25%, totaling 522 million. And operating profit increased by 69%, resulting in 34% operating profit margin and 177 million euros. and earnings per share was one euro. And of course, in our net sales development, innovative medicines was the main driver by 95 million euros. But also when we look at branded products ...